TONMYA Access Expands
Tonix Pharmaceuticals Broadens TONMYA Access to 52 Million Commercial Lives for Fibromyalgia
Anonymous
Tonix Pharmaceuticals announced a second group purchasing organization coverage agreement for TONMYA, effective June 1, 2026, adding access for about 17 million more U.S. commercial lives and bringing total commercial coverage to roughly 52 million lives, or about 29% of the estimated 177 million commercially insured Americans. The company says TONMYA is also available through Medicaid programs covering about 75 million lives, with discussions ongoing for Medicare access. TONMYA is positioned as a non-opioid cyclobenzaprine sublingual treatment taken at bedtime for long-term use and is the first new FDA-approved prescription option for fibromyalgia in more than 15 years. Tonix described the two GPO deals as an early milestone to broaden patient access for a condition affecting more than 10 million U.S. adults. The news helped lift Tonix’s shares in trading tied to the announcement, reflecting investor focus on expanding payer coverage for its flagship therapy.
Key Points
1
Tonix CEO Seth Lederman, M.D. said the two-GPO coverage milestone is “an important milestone in expanding patient access in the early phase of our commercial launch.”
2
Benzinga reported TONMYA was approved by the FDA on August 15 and is the first new prescription medicine for fibromyalgia in more than 15 years.
3
The drug’s specific product formulation was described as cyclobenzaprine HCl sublingual tablets 2.8 mg (TONMYA).
4
Investor reaction: Benzinga said Tonix shares were up 6.14% at $11.75, while Investing.com reported shares rose 4.7% in premarket trading.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
10
Articles
19
Reach
29
Topics
A
AnonymousAuthor
